AstraZeneca pauses £200mn Cambridge investment
SEPT 13 - AstraZeneca has paused plans to invest £200m at a Cambridge research site in a fresh blow to the UK pharmaceutical industry. The project, which Kenya breaking news | Kenya news today |..
✨ Key Highlights
AstraZeneca has paused plans to invest £200 million at a Cambridge research site, a move that would have created 1,000 jobs. This decision represents a fresh blow to the UK pharmaceutical industry, following a similar withdrawal by US pharmaceutical giant Merck.
- AstraZeneca's Cambridge expansion, announced in March 2024, is now paused.
- The pause comes after Merck scrapped a £1 billion UK expansion and as President Donald Trump pressures pharmaceutical firms to invest more in the US.
- AstraZeneca previously scrapped plans to invest £450 million in a vaccine manufacturing plant in Merseyside in January.
- UK spending on medicines has fallen from 15% of the NHS budget to 9% over the last 10 years.
- AstraZeneca announced in July that it would invest $50 billion (£36.9 billion) in the US for "medicines manufacturing and R&D."
Continue Reading
Read the complete article from Capital Business
Part of the Day's Coverage
Fitch Downgrades France's Rating, AstraZeneca Pauses UK Investment, and Protests Damage Nepal's Hotel Sector - September 2025
Rating agency Fitch downgraded France’s long-term sovereign credit rating from AA- to A+, citing the nation's high government debt and political fragmentation. In the United Kingdom, AstraZeneca has paused plans for a £200 million investment at a Cambridge research site, a move that would have created 1,000 jobs and follows a similar withdrawal by US firm Merck. Separately, Nepal's hotel sector has suffered significant financial losses exceeding 25 billion Nepali rupees due to recent protests. Numerous hotels experienced extensive damage from vandalism and arson attacks on September 9.
